Almirall Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Almirall heeft een totaal eigen vermogen van €1.5B en een totale schuld van €365.6M, wat de schuld-eigenvermogensverhouding op 24.6% brengt. De totale activa en totale passiva bedragen respectievelijk €2.3B en €834.8M. De EBIT Almirall is €41.4M waardoor de rentedekking 5.9 is. Het heeft contanten en kortetermijnbeleggingen van €330.9M.

Belangrijke informatie

24.6%

Verhouding schuld/eigen vermogen

€365.62m

Schuld

Rente dekkingsratio	5.9x
Contant	€330.88m
Aandelen	€1.49b
Totaal verplichtingen	€834.81m
Totaal activa	€2.32b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( €693.2M ) ALME } overtreffen de korte termijn passiva ( €274.0M ).

Langlopende schulden: De kortetermijnactiva ALME ( €693.2M ) overtreffen de langetermijnschulden ( €560.8M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 2.3% ) ALME wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van ALME is de afgelopen 5 jaar gedaald van 44.6% naar 24.6%.

Schuldendekking: De schuld van ALME wordt goed gedekt door de operationele kasstroom ( 28.1% ).

Rentedekking: De rentebetalingen op de schuld van ALME worden goed gedekt door EBIT ( 5.9 x dekking).

Almirall Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Almirall, S.A. Reiterates Earnings Guidance for Full Year 2024

Almirall, S.A. Reiterates Financial Guidance for Full Year 2024

Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year

Dividend of €0.15 announced

Almirall, S.A. Provides Earnings Guidance for Full Year 2024

First quarter 2024 earnings released

Almirall, S.A., Annual General Meeting, May 10, 2024

Almirall, S.A. Provides Earnings Guidance for the Year 2024

Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis

Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022)

Almirall, S.A. Revises Earnings Guidance for the Year 2023

Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024

Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s Wellbeing

Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million.

First quarter 2023 earnings released

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021)

Almirall, S.A., Annual General Meeting, May 05, 2023

Now 20% undervalued

Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023

Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022

Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic Dermatitis

Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical Study

Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic Dermatitis

Second quarter 2022 earnings released: EPS: €0.039 (vs €0.40 loss in 2Q 2021)

Insufficient new directors

Insufficient new directors

Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 Index

Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis Patients

Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of Lebrikizumab

Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Almirall, S.A. Announces Executive Changes

Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp

Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study

Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in Europe

Almirall, S.A. Receives European Commission Approval of Klisyri® (Tirbanibulin)

Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Adults

Almirall Receives Positive CHMP Opinion for Klisyri®? (Tirbanibulin), an Innovative Topical Treatment for Actinic Keratosis

First quarter 2021 earnings released: EPS €0.17 (vs €0.28 in 1Q 2020)

Full year 2020 earnings released: EPS €0.42 (vs €0.61 in FY 2019)

Revenue misses expectations

Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis

Almirall and MC2 Therapeutics Enters a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for treatment of Plaque Psoriasis

Almirall, S.A. Announces New Publication in the British Journal of Dermatology of ILUMETRI

Almirall, S.A. Announces Executive Changes

Almirall and Happify Health Enter into Strategic Partnership to Develop Evidence-Supported Digital Therapeutics Solutions for Psoriasis Patients

New 90-day high: €12.00

Almirall, S.A. and Tyris Therapeutics Enter into Strategic Partnership to Develop Next Generation Gene Therapies

New 90-day high: €11.29

Almirall, S.A. Announces U.S. Food and Drug Administration Approval of Klisyri® (Tirbanibulin), A New Innovative Topical Treatment for Actinic Keratosis

Popit and Almirall Start Offering New Support Tool to Help Psoriasis Patients

Almirall, S.A. Announces Promotion of Pablo Alvarez as President of Almirall US

Almirall, S.A. Announces Resignation of Peter Guenter as Chief Executive Officer at the End of the Year

Almirall, S.A. Announces Full 5 Year Data Analysis from Two Phase III Clinical Studies, reSURFACE 1 and reSURFACE2 of ILUMETRI

Almirall, S.A. Announces Approval of the Reimbursed Price for Ilumetri® (Tildrakizumab) in France for the Treatment of Adult Patients with Severe Chronic Plaque Psoriasis

Almirall, S.A. and the University of Dundee Announce Multi-Target Research Collaboration to Develop Novel Targeted Protein Degraders Medicines

Neuraxpharm Italy SpA acquired Ansiolin Brand from Almirall, S.A. (BME:ALM).

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven